CClinicalTrials.gg
Enrolling by invitationNCT06472362Updated Sep 11, 2025

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

An observational study in Systemic Sclerosis, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Enrolling by invitation at 7 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,000
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.

Read the detailed description

Interstitial lung disease (ILD or lung fibrosis=stiffening of the lungs by scar tissue) develops in over half of patients with systemic sclerosis (SSc). Whilst ILD remains stable in some patients, at least a third have progressively increasing fibrosis. There is a pressing need for accurate indicators that identify a) patients at higher risk of progression, needing immediate treatment to prevent further irreversible ILD; and b) patients at lower risk, not needing treatment.

In this study the prognostic potential and accuracy of machine-learning derived biomarkers to evaluate abnormalities that are difficult to quantify visually will be investigated. Whether novel high resolution computed tomography (HRCT) imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline can predict ILD progression, vasculopathy development, and survival will be investigated in a cohort of approximately 1,000 SSc-ILD patients.

The algorithm scores will be evaluated against survival using Cox proportional hazards modelling, while mixed effects model analysis will be used to assess links with change in lung function: forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), and carbon monoxide transfer coefficient (Kco). The airway algorithm measuring traction bronchiectasis (dilatation of the airways due to surrounding fibrosis) may predict worsening of FVC, reflective of ILD progression. The vessel algorithm may predict decline in KCO, a marker of pulmonary vascular involvement. Exploratory analyses evaluating change in HRCT fibrosis extent over time for patients with repeat HRCTs will also be performed, and whether composite outcomes of change in HRCT and lung function variables improve long term outcome prediction and pave the way to their use in clinical trials and routine clinical use. Patients with trivial changes on CT will also be included to assess for very early changes that could be predictive of future decline. These algorithms will be combined with the findings of our previous study, which suggest that a certain type of pattern on CT called UIP predicts shorter survival.

02

Conditions studied

  • Systemic Sclerosis

Browse trials for

03

In context

Scleroderma, Systemic

688 studies on the registry are indexed under Scleroderma, Systemic; 223 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 100 across 169 observational studies indexed under Scleroderma, Systemic.

Browse Scleroderma, Systemic studies →

Lead sponsor

Royal Brompton & Harefield NHS Foundation Trust is the lead sponsor of 137 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Secondary/tertiary care patients with SSc

Inclusion criteria

  • diagnosed with SSc
  • ≥18 years old
  • HRCT between 01/01/1990 and 31/12/2019

Exclusion criteria

Exclusion Criteria:

  • Patients who do not have SSc
  • \<18 years old
  • lack of availability of HRCT imaging data
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testHRCT biomarkers

    HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis

06

What researchers measure

Primary outcomes

  1. Survival

    Transplant-free survival

    Time frame: 15 years

  2. Pulmonary hypertension

    Development of pulmonary hypertension

    Time frame: 15 years

  3. Decline in FVC

    Change in lung function measure FVC

    Time frame: 15 years

  4. Decline in DLCO

    Change in lung function measure DLCO

    Time frame: 15 years

  5. Decline in KCO

    Change in lung function measure KCO

    Time frame: 15 years

07

Study locations

7 sites
  • Bichat-Claude Bernard hospital
    Paris, France
  • Hanover Medical School
    Hanover, Germany
  • Marche Polytechnic University
    Ancona, Italy
  • Sassari University
    Sassari, Italy
  • Siena University Hospital
    Siena, Italy
  • Leeds Hospital/University of Leeds
    Leeds, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06472362
Lead sponsor
Royal Brompton & Harefield NHS Foundation Trust
Collaborators
Imperial College London, Royal Free and University College Medical School, The Leeds Teaching Hospitals NHS Trust, Hannover Medical School, University of Siena, Università Politecnica delle Marche, Azienda Ospedaliero Universitaria di Sassari, Bichat Hospital
Responsible party
Sponsor
First posted
Jun 25, 2024
Start date
Nov 1, 2024
Primary completion
Dec 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Sep 11, 2025

Study contacts

Elisabetta A Renzoni
principal investigator · Royal Brompton and Harefield Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion